Table 3.
Peri- and postoperative outcomes of RASP by study
| Variable | Fuschi et al. [11••] | Kim et al. [7] | Umari et al. [10] | Zhang et al. [6] |
|---|---|---|---|---|
| Cohort size | 32 | 33 | 81 | 32 |
| Length of follow-up (months) | 3 mo | 6 mo | 12 mo | - |
| Operative time (minutes) | 138.47 | 128.6 | 105 | 274** |
| Qmax (mL/sec) |
Pre: 7.24 Post:19.45 |
Δ = 13.2 |
Pre: 8 Post: 23 |
- |
| PVR (mL) |
Pre: 126.06 Post: 31.21 |
Δ = 98.9 |
Pre: 73 Post: 0 |
- |
| IPSS |
Pre: 24.3 Post: 8.09 |
Δ = 11.3 |
Pre: 25 Post: 5 |
Pre: 24 Post: 0 |
| QOL |
Pre: 3.83 Post: 1.69 |
Δ = 2.2 | - | - |
| LOS (days) | 3.84** | 7.1** | 4** | 2.3** |
| LOC (days) | 4.14** | 7.0** | 3** | 8** |
| Transfusion rates | - | 0 | 1/81 | 3/32** |
| Re-catheterization rates | - | 0 | 2/81 | 2/32 |
| Cost ($) | - | 7287 | - | - |
Qmax maximum flow rate, PVR post-void residual volume, IPSS International Prostate Symptom Score, QOL quality of life (of IPSS-QOL), LOS length of hospital stay, LOC length of catheterization, Pre before surgery, Post after surgery
**Denotes significant difference to comparison cohort. Unreported data is represented by hyphen. Pre-operative and post-operative difference denoted by Δ